These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 28266877)
1. Glucuronidation: driving factors and their impact on glucuronide disposition. Yang G; Ge S; Singh R; Basu S; Shatzer K; Zen M; Liu J; Tu Y; Zhang C; Wei J; Shi J; Zhu L; Liu Z; Wang Y; Gao S; Hu M Drug Metab Rev; 2017 May; 49(2):105-138. PubMed ID: 28266877 [TBL] [Abstract][Full Text] [Related]
2. Interplay of Efflux Transporters with Glucuronidation and Its Impact on Subcellular Aglycone and Glucuronide Disposition: A Case Study with Kaempferol. Li Y; Lu L; Wang L; Qu W; Liu W; Xie Y; Zheng H; Wang Y; Qi X; Hu M; Zhu L; Liu Z Mol Pharm; 2018 Dec; 15(12):5602-5614. PubMed ID: 30376625 [TBL] [Abstract][Full Text] [Related]
3. Metabolic Disposition of Luteolin Is Mediated by the Interplay of UDP-Glucuronosyltransferases and Catechol-O-Methyltransferases in Rats. Wang L; Chen Q; Zhu L; Li Q; Zeng X; Lu L; Hu M; Wang X; Liu Z Drug Metab Dispos; 2017 Mar; 45(3):306-315. PubMed ID: 28031430 [TBL] [Abstract][Full Text] [Related]
4. Transport-Glucuronidation Classification System and PBPK Modeling: New Approach To Predict the Impact of Transporters on Disposition of Glucuronides. Ge S; Wei Y; Yin T; Xu B; Gao S; Hu M Mol Pharm; 2017 Sep; 14(9):2884-2898. PubMed ID: 28221813 [TBL] [Abstract][Full Text] [Related]
5. Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans. Patel M; Eberl HC; Wolf A; Pierre E; Polli JW; Zamek-Gliszczynski MJ J Pharmacol Exp Ther; 2019 Aug; 370(2):269-277. PubMed ID: 31175220 [TBL] [Abstract][Full Text] [Related]
6. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides. Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243 [TBL] [Abstract][Full Text] [Related]
7. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Xu H; Kulkarni KH; Singh R; Yang Z; Wang SW; Tam VH; Hu M Mol Pharm; 2009; 6(6):1703-15. PubMed ID: 19736994 [TBL] [Abstract][Full Text] [Related]
8. Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Mano Y; Usui T; Kamimura H Drug Metab Dispos; 2007 Jul; 35(7):1182-7. PubMed ID: 17446261 [TBL] [Abstract][Full Text] [Related]
9. Regioselective Glucuronidation of Diosmetin and Chrysoeriol by the Interplay of Glucuronidation and Transport in UGT1A9-Overexpressing HeLa Cells. Zeng X; Shi J; Zhao M; Chen Q; Wang L; Jiang H; Luo F; Zhu L; Lu L; Wang X; Liu Z PLoS One; 2016; 11(11):e0166239. PubMed ID: 27832172 [TBL] [Abstract][Full Text] [Related]
10. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine. Docci L; Umehara K; Krähenbühl S; Fowler S; Parrott N AAPS J; 2020 Oct; 22(6):128. PubMed ID: 33033903 [TBL] [Abstract][Full Text] [Related]
11. Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Seo KA; Bae SK; Choi YK; Choi CS; Liu KH; Shin JG Drug Metab Dispos; 2010 Nov; 38(11):2007-13. PubMed ID: 20713656 [TBL] [Abstract][Full Text] [Related]
12. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203 [TBL] [Abstract][Full Text] [Related]
13. Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9. Gao R; Li L; Xie C; Diao X; Zhong D; Chen X Drug Metab Dispos; 2012 Mar; 40(3):556-67. PubMed ID: 22184458 [TBL] [Abstract][Full Text] [Related]
14. The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. Malfatti MA; Ubick EA; Felton JS Carcinogenesis; 2005 Nov; 26(11):2019-28. PubMed ID: 15944213 [TBL] [Abstract][Full Text] [Related]
15. Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. Qi C; Fu J; Zhao H; Xing H; Dong D; Wu B Xenobiotica; 2019 Mar; 49(3):276-283. PubMed ID: 29436891 [TBL] [Abstract][Full Text] [Related]
17. In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases. Tong Z; Li H; Goljer I; McConnell O; Chandrasekaran A Drug Metab Dispos; 2007 Dec; 35(12):2203-10. PubMed ID: 17875670 [TBL] [Abstract][Full Text] [Related]
18. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Innocenti F; Iyer L; Ramírez J; Green MD; Ratain MJ Drug Metab Dispos; 2001 May; 29(5):686-92. PubMed ID: 11302935 [TBL] [Abstract][Full Text] [Related]
19. Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells. Wei Y; Wu B; Jiang W; Yin T; Jia X; Basu S; Yang G; Hu M Mol Pharm; 2013 May; 10(5):1736-50. PubMed ID: 23402418 [TBL] [Abstract][Full Text] [Related]
20. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Miners JO; Knights KM; Houston JB; Mackenzie PI Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]